Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic...

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Diffuse large B-cell lymphoma (DLBCL) comprises at least five subtypes, including the MCD/C5 cluster defined by MYD88, BCL2, PRDM1, and/or SPIB aberrations.
• Relapsed/refractory DLBCL presents a significant clinical challenge with poor patient outcomes.

Discussion:

• Mouse models with B cell-specific Prdm1 or Spib alterations on a background of oncogenic Myd88 and Bcl2 lesions were generated.
• Molecular analyses revealed that Prdm1- or Spib-altered lymphomas resemble pre-memory and light-zone B cells, while others are enriched for late light-zone and plasmablast gene sets.

Key Insights:

• Combined BTK/BCL2 inhibition demonstrated therapeutic efficacy in preclinical models and in a subset of relapsed/refractory DLBCL patients.
• Prdm1-altered lymphomas exhibited immunogenicity, actionable PD-L1 expression, and sensitivity to anti-CD19 CAR-T cell therapy in vivo.

Outlook:

• These findings highlight the potential of targeted therapies and immunotherapy for specific DLBCL subtypes.
• Further research into the immunobiology and therapeutic vulnerabilities of DLBCL subtypes is warranted.